ARGX (argenx SE) Total Liabilities: $0 Mil (As of Mar. 2026)


ARGX argenx SE ARGX
80 GF Score
Price $939.00
GF Value $1,382.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Total Liabilities?

argenx SE ARGX +3.37% 80 Total Liabilities is $0 Mil as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,382.72 (Significantly Undervalued). The stock has 5 warning signs investors should review.

argenx SE's Total Liabilities for the quarter that ended in Mar. 2026 was $0 Mil.

argenx SE's quarterly Total Liabilities increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($1,359.61 Mil) but then declined from Dec. 2025 ($1,359.61 Mil) to Mar. 2026 ($0.00 Mil).

argenx SE's annual Total Liabilities increased from Dec. 2023 ($444.95 Mil) to Dec. 2024 ($704.24 Mil) and increased from Dec. 2024 ($704.24 Mil) to Dec. 2025 ($1,359.61 Mil).

argenx SE Total Liabilities Historical Data

* Premium members only.

The historical data trend for argenx SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Total Liabilities Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 316.05 320.56 444.95 704.24 1,359.61

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,079.84 0.00 1,359.61 0.00
ARGX
80GF Score
argenx SE ARGX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

argenx SE's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1320.186+(36.327+7.4606987254811E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+3.093+0)
=1,360

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=8682.698-7323.092
=1,360

argenx SE's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0 Mil mean?
argenx SE (ARGX) has a Total Liabilities of $0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for argenx SE and its competitors.
Is argenx SE's Total Liabilities too high?
argenx SE's current Total Liabilities is $0 Mil. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Total Liabilities compare to VRTX and REGN?
argenx SE's Total Liabilities of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for argenx SE and its competitors. argenx SE's current Total Liabilities is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,382.72, compared to a current price of $939.00 — trading 32.1% below its estimated fair value. The current Total Liabilities is $0 Mil. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For argenx SE (ARGX), the current Total Liabilities is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $939.00 is trading 32.1% below its estimated GF Value™ of $1,382.72. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Total Liabilities: $0 Mil
  • GF Value™: $1,382.72 vs. price of $939.00 (32.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for ARGX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$939.00
Price
$1,382.72
GF Value